(MGN) is a slowly progressive disease of the kidney that leads to changes and inflammation of the structures inside the kidney that help filter wastes and fluids. Membranous Nephropathy (MN) affects men twice as often as women and is more common in adults between the ages of 40 and 70.
It develops slowly, over a number of years and people may not realise they have the disorder. Some are identified simply because they are found to have a lot of protein in their urine after a routine test. subepithelial immune-complex deposition – Diffuse granular and complement deposition along GBM – Different isotypes depending on etiology – Can also have mesangial immune complex deposition (more typical of secondary forms.
We stratified patients into three age categories: <65, 65–70, and ≥71 years old. Clinical characteristics were compared between these three groups using a Wilcoxon rank-sum test or Fisher’s exact test. In approximately 25% of cases the disease is secondary, being greater the percentage in children and elderly patients.
Treating or not (MN) has been a matter of controversy for decades. Some authors emphasize rates of spontaneous remission is considered high and argue against while others reinforce the high frequency of progression to and are favorable to IMS. In 1992, Cameron defended the idea that identifying patients at risk to progress to renal failure could give a clue of whom should be treated.
A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy. New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy. PLA2R1 is a large transmembrane receptor of 180-kDa that belongs to the Early PLA2R1 physiological roles include the clearance of sPLA2 from the extracellular medium and/or promotion of their actions.